|
Nov 20
|
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
|
|
Nov 20
|
Sage’s string of research failures continues
|
|
Nov 20
|
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
|
|
Oct 17
|
Sage lays off 55% of R&D workforce and refocuses pipeline
|
|
Oct 17
|
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
|
|
Oct 17
|
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
|
|
Oct 17
|
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
|
|
Oct 17
|
Sage to cut one-third of workforce, streamline drug pipeline
|
|
Oct 17
|
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
|
|
Oct 15
|
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
|
|
Oct 10
|
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
|
|
Oct 9
|
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
|
|
Oct 8
|
Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
|
|
Oct 8
|
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
|
|
Oct 8
|
Sage continues downslide as Alzheimer’s study fails
|
|
Oct 8
|
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
|
|
Oct 8
|
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
|
|
Oct 7
|
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
|
|
Oct 4
|
Sector Update: Health Care Stocks Steady Late Afternoon
|
|
Oct 4
|
Sector Update: Health Care Stocks Softer Friday Afternoon
|